Antibiotics: Global Strategic Business Report

Report
266 Pages
April 2024
Region: Global
Global Industry Analysts, Inc
ID: 358604

Global Antibiotics Market to Reach $50.3 Billion by 2030

The global market for Antibiotics estimated at US$41.4 Billion in the year 2022, is projected to reach a revised size of US$50.3 Billion by 2030, growing at a CAGR of 2.5% over the analysis period 2022-2030. Penicillin, one of the segments analyzed in the report, is projected to record 2.8% CAGR and reach US$15.7 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Cephalosporin segment is readjusted to a revised 3.5% CAGR for the next 8-year period.

The U.S. Market is Estimated at $11.3 Billion, While China is Forecast to Grow at 4.9% CAGR

The Antibiotics market in the U.S. is estimated at US$11.3 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$10.2 Billion by the year 2030 trailing a CAGR of 4.9% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 1% and 1.8% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 1.6% CAGR.

Select Competitors (Total 209 Featured) -

Abbott Laboratories, Inc.
Allergan PLC
Aurobindo Pharma Ltd.
Bayer AG
Eli Lilly and Company
F. Hoffmann-La Roche AG
GlaxoSmithKline PLC
Lupin Pharmaceuticals, Inc.
Merck & Co., Inc.
Mylan NV
Novartis International AG
Pfizer, Inc.
Sanofi
Shionogi, Inc.
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.

What's New?

Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
Global competitiveness and key competitor percentage market shares
Market presence across multiple geographies - Strong/Active/Niche/Trivial
Online interactive peer-to-peer collaborative bespoke updates
Access to digital archives and Research Platform
Complimentary updates for one year

I. METHODOLOGYII. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

Influencer Market Insights
World Market Trajectories
Antibiotics - Global Key Competitors Percentage Market Share in 2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

Table 1: World Recent Past, Current & Future Analysis for Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
Table 2: World Historic Review for Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 3: World 16-Year Perspective for Antibiotics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2023 & 2030
Table 4: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
Table 5: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 6: World 16-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
Table 7: World Recent Past, Current & Future Analysis for Penicillin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
Table 8: World Historic Review for Penicillin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 9: World 16-Year Perspective for Penicillin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
Table 10: World Recent Past, Current & Future Analysis for Cephalosporin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
Table 11: World Historic Review for Cephalosporin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 12: World 16-Year Perspective for Cephalosporin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
Table 13: World Recent Past, Current & Future Analysis for Macrolides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
Table 14: World Historic Review for Macrolides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 15: World 16-Year Perspective for Macrolides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
Table 16: World Recent Past, Current & Future Analysis for Fluoroquinolones by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
Table 17: World Historic Review for Fluoroquinolones by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 18: World 16-Year Perspective for Fluoroquinolones by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
Table 19: World Recent Past, Current & Future Analysis for Tetracycline by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
Table 20: World Historic Review for Tetracycline by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 21: World 16-Year Perspective for Tetracycline by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
Table 22: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
Table 23: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 24: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
Table 25: World Recent Past, Current & Future Analysis for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
Table 26: World Historic Review for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 27: World 16-Year Perspective for Parenteral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
Table 28: World Recent Past, Current & Future Analysis for Other Routes of Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
Table 29: World Historic Review for Other Routes of Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 30: World 16-Year Perspective for Other Routes of Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
Table 31: World Antibiotics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030

III. MARKET ANALYSIS

UNITED STATES

Antibiotics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
Table 32: USA Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 33: USA Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 34: USA 16-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2014, 2023 & 2030
Table 35: USA Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 36: USA Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 37: USA 16-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2014, 2023 & 2030

CANADA

Table 38: Canada Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 39: Canada Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 40: Canada 16-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2014, 2023 & 2030
Table 41: Canada Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 42: Canada Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 43: Canada 16-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2014, 2023 & 2030

JAPAN

Antibiotics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
Table 44: Japan Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 45: Japan Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 46: Japan 16-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2014, 2023 & 2030
Table 47: Japan Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 48: Japan Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 49: Japan 16-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2014, 2023 & 2030

CHINA

Antibiotics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
Table 50: China Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 51: China Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 52: China 16-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2014, 2023 & 2030
Table 53: China Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 54: China Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 55: China 16-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2014, 2023 & 2030

EUROPE

Antibiotics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
Table 56: Europe Recent Past, Current & Future Analysis for Antibiotics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
Table 57: Europe Historic Review for Antibiotics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 58: Europe 16-Year Perspective for Antibiotics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2023 & 2030
Table 59: Europe Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 60: Europe Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 61: Europe 16-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2014, 2023 & 2030
Table 62: Europe Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 63: Europe Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 64: Europe 16-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2014, 2023 & 2030

FRANCE

Antibiotics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
Table 65: France Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 66: France Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 67: France 16-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2014, 2023 & 2030
Table 68: France Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 69: France Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 70: France 16-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2014, 2023 & 2030

GERMANY

Antibiotics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
Table 71: Germany Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 72: Germany Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 73: Germany 16-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2014, 2023 & 2030
Table 74: Germany Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 75: Germany Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 76: Germany 16-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2014, 2023 & 2030

ITALY

Table 77: Italy Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 78: Italy Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 79: Italy 16-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2014, 2023 & 2030
Table 80: Italy Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 81: Italy Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 82: Italy 16-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2014, 2023 & 2030

UNITED KINGDOM

Antibiotics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
Table 83: UK Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 84: UK Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 85: UK 16-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2014, 2023 & 2030
Table 86: UK Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 87: UK Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 88: UK 16-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2014, 2023 & 2030

SPAIN

Table 89: Spain Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 90: Spain Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 91: Spain 16-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2014, 2023 & 2030
Table 92: Spain Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 93: Spain Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 94: Spain 16-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2014, 2023 & 2030

RUSSIA

Table 95: Russia Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 96: Russia Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 97: Russia 16-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2014, 2023 & 2030
Table 98: Russia Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 99: Russia Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 100: Russia 16-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2014, 2023 & 2030

REST OF EUROPE

Table 101: Rest of Europe Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 102: Rest of Europe Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 103: Rest of Europe 16-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2014, 2023 & 2030
Table 104: Rest of Europe Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 105: Rest of Europe Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 106: Rest of Europe 16-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2014, 2023 & 2030

ASIA-PACIFIC

Antibiotics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
Table 107: Asia-Pacific Recent Past, Current & Future Analysis for Antibiotics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
Table 108: Asia-Pacific Historic Review for Antibiotics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 109: Asia-Pacific 16-Year Perspective for Antibiotics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2023 & 2030
Table 110: Asia-Pacific Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 111: Asia-Pacific Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 112: Asia-Pacific 16-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2014, 2023 & 2030
Table 113: Asia-Pacific Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 114: Asia-Pacific Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 115: Asia-Pacific 16-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2014, 2023 & 2030

AUSTRALIA

Antibiotics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2023 (E)

INDIA

Antibiotics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2023 (E)

SOUTH KOREAREST OF ASIA-PACIFIC

LATIN AMERICA

Antibiotics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2023 (E)

ARGENTINABRAZILMEXICOREST OF LATIN AMERICA

MIDDLE EAST

Antibiotics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2023 (E)

IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST

AFRICA

Antibiotics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2023 (E)

IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

Abbott Laboratories, Inc.
Allergan PLC
Aurobindo Pharma Ltd.
Bayer AG
Eli Lilly and Company
F. Hoffmann-La Roche AG
GlaxoSmithKline PLC
Lupin Pharmaceuticals, Inc.
Merck & Co., Inc.
Mylan NV
Novartis International AG
Pfizer, Inc.
Sanofi
Shionogi, Inc.
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.

Table Information

Report Attribute	Details
No. of Pages	266
Published	April 2024
Forecast Period	2020 - 2027
Estimated Market Value ( USD ) in 2020	$ 38.1 Billion
Forecasted Market Value ( USD ) by 2027	$ 45.5 Billion
Compound Annual Growth Rate	2.6%
Regions Covered	Global

PURCHASE OPTIONS

Single User License PDF

1 - 10 User License PDF

Enterprise License PDF

need a quote ?

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€5303EUR$5,450USD£4,543GBP
1 - 10 USER LICENSE PDF	The product is a PDF.	This is a 1-10 user license, allowing up to ten users have access to the product.	€10075EUR$10,355USD£8,631GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€15908EUR$16,350USD£13,628GBP

Global Antibiotics Market to Reach $50.3 Billion by 2030

The U.S. Market is Estimated at $11.3 Billion, While China is Forecast to Grow at 4.9% CAGR

Select Competitors (Total 209 Featured) -

What's New?

Table of Contents

Companies Mentioned (Partial List)

Table Information

Related Topics

Related Reports

Global Antibiotics Market - Distribution by Type of Drug Class, Target Disease Indication, Type of Therapy (Monotherapies and Combination Therapies), Route of Administration and Key Geographical Regions: Industry Trends and Global Forecasts, 2023-2035

EU - Antibiotics - Market Analysis, Forecast, Size, Trends and Insights

Antibacterial Drugs: Global Strategic Business Report

Antibiotics Market Report by Action Mechanism, Drug Class, Spectrum of Activity, Route of Administration, End User, and Region 2023-2028

Antibiotics Global Market Report 2024